|
|
| ARASENS: A Phase 3 Trial of Darolutamide in Combination with Docetaxel for Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Journal Club |
Zachary Klaassen, MD, MSc and Chris Wallis, MD, Ph.D.
Christopher Wallis and Zachary Klaassen highlight the New England Journal of Medicine publication on the international, phase 3 ARASENS trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights from the 2022 American Society of Clinical Oncology Annual Meeting |
|
|
|
|
|
Poster Session: Genitourinary Cancer--Prostate Cancer
|
|
| Cohort Study of Patients With Oligorecurrent Prostate Cancer: Oncological Outcomes of Patients Treated With Salvage Lymph Node Dissection via PSMA Radioguided Surgery |
| Sophie Knipper, MD |
| At the 2022 American Society of Clinical Oncology Annual Meeting held in Chicago and virtually, the poster session focused on Prostate, Testicular, and Penile cancers on Monday afternoon included a presentation from Dr. Sophie Knipper discussing prostate-specific membrane antigen (PSMA)-guided radiosurgery for oligorecurrent prostate cancer. |
|
|
|
|
|
| PSMA PET Response Associates With rPFS Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer |
| Philip Sutera, MD |
| Philip Sutera discussed the association prostate specific membrane antigen (PSMA) response and radiographic-progression free survival among patients treated with stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer. |
|
|
|
|
|
| Phase II, Double-Blind, Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial |
| Phuoc T. Tran, MD, Ph.D. |
| Phuoc Tran presented the results of the SALV-ENZA trial, a phase II study assessing salvage radiotherapy with or without enzalutamide for patients with high-risk PSA-recurrence following radical prostatectomy for prostate cancer. The combination of salvage radiotherapy with enzalutamide monotherapy for men with PSA recurrent high-risk prostate cancer following RP is safe and delays PSA progression relative to salvage radiotherapy alone. |
|
|
|
|
|
| Local and Focal: What’s Next in Salvage Therapy? - Discussion |
| Mark Garzotto, MD |
| Mark Garzotto provided a discussion of salvage therapies in patients with prostate cancer. Short-term enzalutamide improved biochemical recurrence with a favourable toxicity profile. However, clinically meaningful endpoints remain to be assessed. Given the recently demonstrated benefit of novel hormonal therapies in the non-metastatic castration sensitive space along with primary radiotherapy for high-risk disease, these data suggest that treatment intensification may have a role earlier in the disease process. |
|
|
|
|
|
|
|
|
|
|
| Phase 1b Study of Bavdegalutamide, an Androgen Receptor PROTAC Degrader, Combined with Abiraterone in Patients with Metastatic Prostate Cancer |
| Neal Shore, MD, FACS |
| The 2022 ASCO annual meeting featured a session on prostate cancer, including a trial in progress presentation by Dr. Neal Shore discussing a phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer. Bavdegalutamide (ARV-110) is a novel, oral PROteolysis TArgeting Chimera (PROTAC) protein degrader that targets wild-type androgen receptor and clinically relevant mutants. |
|
|
|
|
|
| A Phase III Double Blinded Study of Early Intervention After Radical Prostatectomy with ADT with Darolutamide Versus Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE) |
| Alicia Morgans, MD, MPH |
| Alicia Morgans discussed ERADICATE, a phase III double blinded study of early intervention after radical prostatectomy with ADT with darolutamide versus placebo in men at highest risk of prostate cancer metastasis by genomic stratification. |
|
|
|
|
|
| Targeting B7-H3 in Prostate Cancer: Phase 2 Trial in Localized Prostate Cancer Using the Anti-B7-H3 Antibody Enoblituzumab, with Biomarker Correlatives |
| Eugene Shenderov, MD, Ph.D. |
| Eugene Shenderov discussing a phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab. In this neoadjuvant trial, inhibition of B7-H3 with 6 weeks of enoblituzumab demonstrated favorable safety and encouraging activity in localized prostate cancer patients prior to prostatectomy. |
|
|
|
|
|
| A Phase 2 Randomized Study of Oral Docetaxel plus Ritonavir (ModraDoc006/r) in Patients with mCRPC |
| Ulka N. Vaishampayan, MD
|
| Ulka Vaishampayan discussied a phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/ritonavir) in patients with mCRPC. Results of this study indicate that further development of ModraDoc006/ritonavir in mCRPC is warranted. |
|
|
|
|
|
| Bone Biomarkers and Overall Survival in Men with Advanced HSPC: Results from SWOG S1216, a Phase III Trial of ADT +/- Orteronel |
| Primo Lara, MD |
| Primo Lara discussed data from the SWOG S1216 trial of ADT +/- orteronel assessing bone biomarkers and overall survival in men with advanced HSPC. These results validate the clinical value of bone biomarkers in the HSPC state, extending bone biomarkers utility beyond CRPC. |
|
|
|
|
|
| Prevalence of DNA Damage Repair Alterations in Patients with mHSPC Receiving Enzalutamide or Placebo + ADT: ARCHES Post Hoc Analysis |
| Arun Azad, Ph.D. |
| Arun Azad discussed a post hoc analysis of the ARCHES trial assessing the prevalence of DNA damage repair (DDR) alterations in patients with mHSPC receiving enzalutamide or placebo + ADT. This post hoc analysis found a lower prevalence of germline DDR alterations in patients with mHSPC in ARCHES, compared with the 7–8% previously reported in patients with metastatic castration-resistant prostate cancer. |
|
|
|
|
|
| Familiar Faces and New Directions for Prostate Cancer - Discussion |
| Bradley C. Carthon, MD, Ph.D. |
| Bradley Carthon discussed familiar faces and new directions for prostate cancer. For this discussant presentation, Dr. Carthon discussed three abstracts including “Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives” presented by Eugene Shenderov, “A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with mCRPC” presented by Ulka Vaishampayan, and “PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with mCRPC” presented by Shahneen Sandhu. |
|
|
|
|
|
| BRCAAway: A Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects |
| Maha Hussain, MD, FACP, FASCO
|
| Maha Hussain discussed the BRCAAway trial, a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with mCRPC with DNA repair defects. Dr. Hussain emphasized that in mCRPC patients with inactivating BRCA1, BRCA2, and/or ATM alterations, abiraterone + prednisone + olaparib was well tolerated and resulted in longer PFS and better PSA response versus either agent alone. |
|
|
|
|
|
| Tolerability of Abiraterone Combined with Olaparib in Patients with mCRPC: Further Results from the Phase III PROpel Trial |
| Antoine Thiery-Vuillemin, MD, Ph.D. |
| Antoine Thiery-Vuillemin discussed further results from the PROpel trial assessing tolerability of abiraterone combined with olaparib in patients with mCRPC. The overall results of PROpel demonstrate the clinical benefits of olaparib in combination with abiraterone in the first-line treatment of an unselected population of patients with mCRPC. |
|
|
|
|
|
| Gene-by-Gene Analysis in the MAGNITUDE Study of Niraparib (NIRA) with Abiraterone Acetate and Prednisone (AAP) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Homologous Recombination Repair (HRR) Gene Alterations. |
| Shahneen Sandhu, MD, Ph.D., MBBS, FRACP |
| The double-blind, randomized phase III MAGNITUDE study compared the efficacy of the addition of niraparib (versus placebo) to abiraterone acetate and prednisone (AAP) in the treatment of mCRPC. Here, Dr. Sandhu presented analysis of some of the other genes used in MAGNITUDE as putative biomarkers of PARP sensitivity. |
|
|
|
|
|
|
